Cargando…

Mometasone implant for chronic rhinosinusitis

The Propel mometasone-eluting stent (Intersect ENT, Palo Alto, CA) is the first Food and Drug Administration-approved device for delivering steroid medication into the ethmoid cavity following surgery. The implant is composed of a biodegradable polymer in a lattice pattern that expands in a spring-l...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Calvin C, Kennedy, David W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3496965/
https://www.ncbi.nlm.nih.gov/pubmed/23152712
http://dx.doi.org/10.2147/MDER.S33916
_version_ 1782249692588933120
author Wei, Calvin C
Kennedy, David W
author_facet Wei, Calvin C
Kennedy, David W
author_sort Wei, Calvin C
collection PubMed
description The Propel mometasone-eluting stent (Intersect ENT, Palo Alto, CA) is the first Food and Drug Administration-approved device for delivering steroid medication into the ethmoid cavity following surgery. The implant is composed of a biodegradable polymer in a lattice pattern that expands in a spring-like fashion to conform to the walls of a dissected ethmoid cavity and contains a total of 370 μg of mometasone furoate designed for gradual release over 30 days. The purpose of this article is to review the mode of action and the evidence supporting the efficacy of this novel technology. Three recently published clinical trials have demonstrated that the mometasone-eluting stent produced statistically significant reductions in inflammation, polyp formation, and postoperative adhesions. In addition, the implant has been found to significantly reduce the need for postoperative administration of oral steroids and to decrease the frequency of postoperative lysis of adhesions. Minimal adverse effects were reported in these trials and included infection, crusting, and granulation tissue formation. Although the placement of steroid-impregnated packing, stents, sponges, and gels has previously been used in the postoperative sinus cavities, the Propel mometasone-eluting stent introduces a new mechanism for localized and controlled delivery of topical therapy directly to the nasal mucosa for chronic rhinosinusitis.
format Online
Article
Text
id pubmed-3496965
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-34969652012-11-14 Mometasone implant for chronic rhinosinusitis Wei, Calvin C Kennedy, David W Med Devices (Auckl) Review The Propel mometasone-eluting stent (Intersect ENT, Palo Alto, CA) is the first Food and Drug Administration-approved device for delivering steroid medication into the ethmoid cavity following surgery. The implant is composed of a biodegradable polymer in a lattice pattern that expands in a spring-like fashion to conform to the walls of a dissected ethmoid cavity and contains a total of 370 μg of mometasone furoate designed for gradual release over 30 days. The purpose of this article is to review the mode of action and the evidence supporting the efficacy of this novel technology. Three recently published clinical trials have demonstrated that the mometasone-eluting stent produced statistically significant reductions in inflammation, polyp formation, and postoperative adhesions. In addition, the implant has been found to significantly reduce the need for postoperative administration of oral steroids and to decrease the frequency of postoperative lysis of adhesions. Minimal adverse effects were reported in these trials and included infection, crusting, and granulation tissue formation. Although the placement of steroid-impregnated packing, stents, sponges, and gels has previously been used in the postoperative sinus cavities, the Propel mometasone-eluting stent introduces a new mechanism for localized and controlled delivery of topical therapy directly to the nasal mucosa for chronic rhinosinusitis. Dove Medical Press 2012-08-17 /pmc/articles/PMC3496965/ /pubmed/23152712 http://dx.doi.org/10.2147/MDER.S33916 Text en © 2012 Wei and Kennedy, publisher and licensee Dove Medical Press Ltd This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Review
Wei, Calvin C
Kennedy, David W
Mometasone implant for chronic rhinosinusitis
title Mometasone implant for chronic rhinosinusitis
title_full Mometasone implant for chronic rhinosinusitis
title_fullStr Mometasone implant for chronic rhinosinusitis
title_full_unstemmed Mometasone implant for chronic rhinosinusitis
title_short Mometasone implant for chronic rhinosinusitis
title_sort mometasone implant for chronic rhinosinusitis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3496965/
https://www.ncbi.nlm.nih.gov/pubmed/23152712
http://dx.doi.org/10.2147/MDER.S33916
work_keys_str_mv AT weicalvinc mometasoneimplantforchronicrhinosinusitis
AT kennedydavidw mometasoneimplantforchronicrhinosinusitis